Moderna Aktie News

The market for artificial intelligence is undergoing a profound transformation, reshaping industries and investment strategies alike. Rapid advancements and integration across sectors and understanding the shifting landscape becomes imperative for investors seeking opportunities in AI.

Investors have worried about Moderna's growth prospects as demand for its coronavirus vaccine declines. Moderna may have a new billion-dollar product right around the corner.

Covid vaccine maker Moderna Inc and partner Merck Sharp and Dohme (MSD) have initiated a phase III trial in the UK for the world's first "personalised" mRNA vaccine, mRNA-4157 (V940), targeting melanoma, the deadliest form of skin cancer. Tailored to each patient's unique genetic tumour markers, the treatment aims to train the immune system to recognise and eliminate cancer cells, potentially p...

CAMBRIDGE, MA / ACCESSWIRE / April 25, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will present data from its respiratory portfolio, including vaccines and vaccine candidates against COVID-19 (mRNA-1273, mRNA-1283), influenza (mRNA-1010, mRNA-1011/1012), and respiratory syncytial virus (RSV) (mRNA-1345), along with data related to its latent virus portfolio regarding cyt...

Generative AI will help advance Moderna's broad and diverse portfolio to maximize the Company's impact on patients Moderna embeds OpenAI's generative AI tools throughout its organization and sees early success with broad adoption of ChatGPT Enterprise CAMBRIDGE, MA AND SAN FRANCISCO, CA / ACCESSWIRE / April 24, 2024 / Moderna, Inc. (NASDAQ:MRNA) and OpenAI today announced their ongoing collabor...

While artificial intelligence may be useful for a variety of purposes – including asking silly questions we're afraid to pose in real life – the ultimate end game for digital intelligence could be to advance the human condition, which brings us to medical AI stocks. When conducted in a controlled environment, AI can help accelerate productivity.

Pfizer and BioNTech asked a London court to revoke rival Moderna's patents over technology key to the development of vaccines for COVID-19, as the latest leg of a global legal battle began on Tuesday.

CAMBRIDGE, MA / ACCESSWIRE / April 22, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced a contract with the Ministry of Health in Brazil (Ministério da Saúde) to supply its mRNA COVID-19 vaccine as an integral part of Brazil's 2024 national vaccination campaign against COVID-19. This contract follows the Brazilian Health Regulatory Agency's (ANVISA) approval of Moderna's COVID-19 vaccine in M...